Statement From Michael Hansen, Ceo Of Elsevier's Health Sciences Division, Regarding Australia Based

< BACK TO RESEARCH starstarstarstarstar   Science - Research Press Release
8th May 2009, 03:11am - Views: 499





Business Company UBM International 1 image






Statement From Michael Hansen, CEO of Elsevier's Health Sciences Division, Regarding Australia

Based Sponsored Journal Practices Between 2000 and 2005


PHILADELPHIA, May 8 /PRNewswire-AsiaNet/ --


    Elsevier, one of the world's leading publishers of scientific, technical, and medical (STM) information

products and services, announced today that Michael Hansen, CEO of Elsevier's Health Sciences Division,

issued the following statement in light of recent allegations of improper Australia based sponsored journal

publication practices between 2000 and 2005:


    "Elsevier prides itself on operating its business in the most ethical, honest and transparent manner possible.

We have been stewards of the scientific record for more than 125 years and we take our role in advancing

medical and scientific research seriously.


    It has recently come to my attention that from 2000 to 2005, our Australia office published a series of

sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look

like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took

place.


    We are currently conducting an internal review but believe this was an isolated practice from a past period

in time. It does not reflect the way we operate today. The individuals involved in the project have long since left

the company. I have affirmed our business practices as they relate to what defines a journal and the proper

use of disclosure language with our employees to ensure this does not happen again.


    We will continue to partner with all scientists and clinical investigators, including those in the pharmaceutical

industry, to help communicate the findings of high-quality, peer-reviewed medical research. We have strict

disclosure rules in place so that readers are aware of any financial interests behind a specific article or journal,

or when entire compilation products are created for pharmaceutical marketing purposes.


    I understand this issue has troubled our communities of authors, editors, customers and employees. But I

can assure all that the integrity of Elsevier's publications and business practices remains intact."


    About Elsevier


    Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over

70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a


http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online

reference works.


    Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and

has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-

leading publisher and information provider. Operating in the science and medical, legal, education, and

business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users,

with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN

(Euronext Amsterdam), REL (London Stock Exchange), RUK, and ENL (New York Stock Exchange).


    Tom Reller, Director, Corporate Relations, Elsevier

    +1-212-462-1912

    T.Reller@Elsevier.com


    SOURCE: Elsevier

__________________________________________________________________________________________

To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article